Treatment of Diabetic Retinopathy by Light-Coagulation: A Preliminary Study

Wetzig, Paul C.; Worlton, James T.

doi:10.1136/bjo.47.9.539

Cited by 36 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One reason is that persons diagnosed in earlier years were less likely to receive retinal photocoagulation treatment for PDR or CSME because such treatment first became available in the early 1960s and its efficacy was demonstrated in randomized controlled clinical trials in the 1970s (Diabetic Retinopathy Study [DRS]) and 1980s (ETDRS) 5,6,26. This is reflected in the WESDR where growing proportions of persons with PDR or CSME had been photocoagulated in subsequent examinations (Klein R, unpublished data).…”

Section: Discussionmentioning

confidence: 99%

Changes in Visual Impairment Prevalence by Period of Diagnosis of DiabetesThe Wisconsin Epidemiologic Study of Diabetic Retinopathy

et al. 2009

View full text Add to dashboard Cite

Objective-To examine relationships of period of diagnosis of type 1 diabetes mellitus (T1DM) to the prevalence of visual impairment (VI). Design-Population-based longitudinal study.Participants-Nine hundred fifty-five persons (3,719 participant visits) 4-80 years of age at baseline who lived in an 11-county area in southern Wisconsin who were diagnosed with T1DM before age 30 years contributed to the prevalence of VI. 1980-1982, 1984-1986, 1990-1992, 1994-1995, and 2005-2007. Age of diagnosis of T1DM was grouped as <1960, 1960-1969, 1970-1974, and 1975-1979. Best corrected visual acuity (VA) using a modification of the Early Treatment Diabetic Retinopathy protocol was measured. Methods-Five eye examination visits occurred inMain Outcome Measures-VI defined as best corrected visual acuity in the better eye of 20/40 or worse.Results-While controlling for duration of T1DM, there was a lower prevalence of VI for more recent periods of diagnosis of diabetes (odds ratio per category 0.91, 95% confidence interval, 0.88, 0.93; P <.0001). This remained while controlling for glycosylated hemoglobin, blood pressure, and other related factors.Conclusions-More recently diagnosed T1DM was associated with lower prevalence of VI. This is likely due to the diminishing incidence of proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME) due to better glycemic control and more timely interventions with photocoagulation for CSME and PDR in those with more recently diagnosed T1DM. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author ManuscriptOphthalmology. Author manuscript; available in PMC 2010 October 1. Persons with diabetes are at higher risk of visual impairment (VI) than nondiabetic persons. 1 This is due to presence of proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME) and to a lesser extent, a higher frequency of cataract and glaucoma in persons with diabetes compared to persons without diabetes. [1][2][3][4] However, visual impairment may be decreasing as a result of implementation of findings from clinical trials that have showed that glycemic control reduces progression of diabetic retinopathy (DR) and that the treatment of vision-threatening diabetic retinopathy prevents vision loss. [5][6][7][8] To address this possibility, we examined the relation of period of diagnosis of type 1 diabetes mellitus (T1DM) to the prevalence of VI over several time intervals when there has been significant change in the management of diabetes and its complications. METHODS Study PopulationCase iden...

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in Visual Impairment Prevalence by Period of Diagnosis of DiabetesThe Wisconsin Epidemiologic Study of Diabetic Retinopathy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…At the present time proliferative lesions, formerly held to lie outside the range of therapy, are being attacked from several fronts with varying degrees of success. For example, the methods of pituitary ablation initiated by Luft, Olivecrona, Kornerup, Ljunggren, Nilsson, and Sj6gren (1956), the lightcoagulation techniques of Meyer-Schwickerath (1960) and Wetzig and Worlton (1963), and the anabolic steroids used by Valk (1960) aim at causing regression of the proliferative lesions. It is of paramount importance therefore, in assessing the effectiveness of treatment, to recognize that Stage III of the spontaneous,changes shows a reduction in new vessels and probably a reduction in the tendency to haemorrhages.…”

Section: Discussionmentioning

confidence: 99%

Proliferative Diabetic Retinopathy: Evolution of the Retinal Lesions

Dobree¹

1964

British Journal of Ophthalmology

View full text Add to dashboard Cite

“…These findings were confirmed with histopathological specimens, such as the work of Arthur Ballantyne, who, in 1945, showed that capillary wall changes contributed to the development of DR [ 1 ]. Laboratory research on endothelial cell dysfunction and clinical observations using fluorescein angiography solidified the paradigm of DR as a vascular disease, and led to early suggestions of using light photocoagulation, or laser therapy, to treat retinopathy in the 1960s [ 2 ]. In 1968, the Airlie House Symposium brought prominent ophthalmologists and researchers in diabetic retinopathy together.…”

Section: Diabetic Retinopathy: Research To Clinical Practice—pastmentioning

confidence: 99%

Diabetic retinopathy: research to clinical practice

Shah

Gardner

2017

Clin Diabetes Endocrinol

View full text Add to dashboard Cite

BackgroundDiabetic Retinopathy (DR) is a leading cause of visual impairment in the United States. The CDC estimates that the prevalence of DR will triple from 2005 to 2050.Main bodyThe report summarizes major past advances in diabetes research and their impact on clinical practice. Current paradigms and future directions are also discussed.ConclusionsDR is a leading cause of visual impairment in the US. Significant progress has been made in the understanding and treatment of DR, but rising prevalence demands innovative approaches to management in the future.

show abstract

Treatment of Diabetic Retinopathy by Light-Coagulation: A Preliminary Study

Cited by 36 publications

References 1 publication

Changes in Visual Impairment Prevalence by Period of Diagnosis of DiabetesThe Wisconsin Epidemiologic Study of Diabetic Retinopathy

Changes in Visual Impairment Prevalence by Period of Diagnosis of DiabetesThe Wisconsin Epidemiologic Study of Diabetic Retinopathy

Proliferative Diabetic Retinopathy: Evolution of the Retinal Lesions

Diabetic retinopathy: research to clinical practice

Contact Info

Product

Resources

About